Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 4/2018

STATINS USE AND RISK OF SARCOPENIA IN COMMUNITY DWELLING OLDER ADULTS

ANNA MARIE HERGHELEGIU 1,2, GABRIEL IOAN PRADA 1,2, RALUCA MIHAELA NACU 2, ANDREI KOZMA 3*, IOANA DANA ALEXA 4

1.National Institute of Geriatrics and Gerontology “Ana Aslan”, 9 Cǎldǎrușani St., Sector 1, Bucharest, Romania
2.University of Medicine and Pharmacy “Carol Davila”, 37 Dionisie Lupu St., Sector 2, Bucharest, Romania
Tel.: 0.21 318.0719/ Fax.: 0.21 318 07 30
3.“Fr. I. Rainer” Anthropology Institute of Romanian Academy, Bucharest, Romania
4.University of Medicine and Pharmacy “Gr.T.Popa”, 16 Universității St., Iasi, Romania

Download Full Article PDF

Current guidelines recommend statin use for cardiovascular risk management in adults as well as older people but in many situations these recommendations feature individualized drug management decisions. Statin induced myalgia and muscular toxicity syndrome are gaining more and more attention especially in older patients with sarcopenia. In this case-control study we investigated the association between long term statin use and risk of sarcopenia. A total number of 368 patients with a mean age of 76.43 met the eligibility criteria and were included in the study. Statin treatment significantly increased the odds of patients’ being at high risk for sarcopenia by a factor of 2.62 (OR = 2.62, 95%CI: 1.53 - 4.46; p < 0.001). The enhanced risk of sarcopenia was associated with lipophilic statins use and positively correlated with the dosage. When correlating the education level, area of residence, income and living arrangements, statin administration remained significantly associated with a high risk for sarcopenia.